Thomas de Vlaam
Thomas de Vlaam joined Flagship Pioneering as an associate in 2021. At Flagship, Thomas works as part of a team of scientist-entrepreneurs on the creation of the next generation of world-changing biotechnology companies. In this role, Thomas is responsible for developing the science, business strategy, and intellectual property from which these new ventures are formed.
Prior to Flagship, Thomas was founder and CEO of Amylon Therapeutics, a biotechnology startup that focused on using RNA therapeutics to treat rare neurodegenerative disease. Thomas created Amylon as a spin-out from ProQR Therapeutics, where he was their Head of Central Nervous System (CNS) Innovation.
Thomas holds a B.Sc. degree in International Medicine and Global Health. His work has resulted in multiple patents and publications. Thomas was elected one of the top 10 young European biotech entrepreneurs by Labiotech, as well as one of the 30 rising leaders in life sciences by Invivo.